BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9713390)

  • 1. Prostate cancer screening.
    Witte MN; Morton RA
    Am Fam Physician; 1998 Aug; 58(2):342, 345-6, 348. PubMed ID: 9713390
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer screening: more harm than good?
    Lefevre ML
    Am Fam Physician; 1998 Aug; 58(2):432-8. PubMed ID: 9713397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer. Examining the risks and benefits of screening.
    Cotter VT
    Adv Nurse Pract; 1998 Jul; 6(7):51-3. PubMed ID: 9782799
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: 4. Screening.
    Meyer F; Fradet Y
    CMAJ; 1998 Oct; 159(8):968-72. PubMed ID: 9834724
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostate cancer. Surgery lengthens survival.
    Hodgson WB
    BMJ; 1998 Jun; 316(7148):1903-4. PubMed ID: 9669857
    [No Abstract]   [Full Text] [Related]  

  • 8. Contemporary view of prostate cancer diagnosis and treatment.
    Costello AJ
    Aust Fam Physician; 2003 Jun; 32(6):396-8. PubMed ID: 12833761
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].
    Damber JE
    Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect.
    Walsh RM; Thompson IM
    J Urol; 2007 Apr; 177(4):1303-6. PubMed ID: 17382719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What will the emperor say? Screening for prostate cancer as of 2008.
    Concato J
    Cancer J; 2009; 15(1):7-12. PubMed ID: 19197166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to prostate cancer care and implications for survival among minorities.
    Oliver MN
    J Urol; 2009 Feb; 181(2):447-8. PubMed ID: 19095248
    [No Abstract]   [Full Text] [Related]  

  • 13. [Screening for cancer of the prostate: a life-saver or a waste of money?].
    Rutishauser G; Graber P; Leisinger HJ; Schmid HP
    Ann Urol (Paris); 1994; 28(4):176-7. PubMed ID: 7979206
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: screening and treatment options.
    Horger DC; Clarke HS
    J S C Med Assoc; 2003 Apr; 99(4):85-7. PubMed ID: 12762154
    [No Abstract]   [Full Text] [Related]  

  • 16. The Scandinavian Prostate Cancer Group Study: the case for conservative management.
    Parker C
    BJU Int; 2005 Nov; 96(7):952-3. PubMed ID: 16225505
    [No Abstract]   [Full Text] [Related]  

  • 17. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 19. Should men over the age of 65 years receive PSA screening? Argument against.
    Albertsen PC
    Nat Clin Pract Urol; 2008 May; 5(5):232-3. PubMed ID: 18349860
    [No Abstract]   [Full Text] [Related]  

  • 20. A misleading paper on prostate cancer screening.
    Elwood M
    Prostate; 2004 Dec; 61(4):372; author reply 373-4. PubMed ID: 15503318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.